Bioavailability and Pharmacokinetics of Oral Topotecan: A New Topoisomerase I Inhibitor

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.1996.243
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Chemistry and Pharmacokinetics of Gallium Maltolate, a Compound With High Oral Gallium Bioavailability

Metal-Based Drugs
2000English

Phase I and Pharmacological Study of the New Topoisomerase I Inhibitor GI147211, Using a Daily X 5 Intravenous Administration

British Journal of Cancer
Cancer ResearchOncology
1996English

Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol After Intravenous and Oral Administration

Clinical Drug Investigation
MedicinePharmacology
2015English

A Systematic Study of Nitrated Indenoisoquinolines Reveals a Potent Topoisomerase I Inhibitor

English

Molecular and Cytotoxic Effects of Camptothecin, a Topoisomerase I Inhibitor, on Trypanosomes and Leishmania.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1995English

Diospyrin, a Bisnaphthoquinone: A Novel Inhibitor of Type I DNA Topoisomerase ofLeishmania Donovani

Molecular Pharmacology
Molecular MedicinePharmacology
1998English

Pharmacokinetics, Oral Bioavailability, and Metabolic Profile of Resveratrol and Its Dimethylether Analog, Pterostilbene, in Rats

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

Pharmacokinetics and Bioavailability of Difloxacin in Camel

Journal of Veterinary Medical Research
2005English

Nonclinical Pharmacokinetics and Activity of Etirinotecan Pegol (NKTR-102), a Long-Acting Topoisomerase 1 Inhibitor, in Multiple Cancer Models

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy